[Use of Pharmacogenetic Information for Therapeutic Drug Monitoring of an Antiarrhythmic Drug].

@article{Doki2018UseOP,
  title={[Use of Pharmacogenetic Information for Therapeutic Drug Monitoring of an Antiarrhythmic Drug].},
  author={Kosuke Doki},
  journal={Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan},
  year={2018},
  volume={138 9},
  pages={
          1145-1150
        }
}
 Antiarrhythmic drugs require therapeutic drug monitoring (TDM) to avoid adverse effects such as proarrhythmia. However, TDM is not necessarily used to adjust the dosage of antiarrhythmic drugs because there is a lack of information regarding the therapeutic range of the serum concentration and the selection of patients who require TDM. The aim of this review was to provide an overview of the pharmacogenetic information on the pharmacokinetics and drug response of flecainide, a class Ic… CONTINUE READING